Dominari Holdings 
Welcome,         Profile    Billing    Logout  
 1 Product   0 Diseases   1 Product   3 Trials   260 News 


«123»
  • ||||||||||  177 Lu PSMA-617 / Excel Diagnostics, Novartis
    [VIRTUAL] Patient-reported outcomes in prostate cancer patients receiving PSMA-targeted radionuclide therapy () -  Jul 22, 2021 - Abstract #ESMO2021ESMO_1979;    
    P1, P1/2
    PROs did not change over time overall or as a function of PSMA-TRT received; however, change in clinically important PROs was associated with response to treatment. Future studies should replicate and extend these findings to examine change in PROs as a potential prognostic factor for response to PSMA-TRT.
  • ||||||||||  Ac-225 rosopatamab tetraxetan (CONV01-?) / Dominari Holdings
    Enrollment closed, Trial primary completion date, Metastases:  7R01CA207645-03: Phase I Trial of 225Ac-J591 in Patients With mCRPC (clinicaltrials.gov) -  Mar 4, 2021   
    P1,  N=31, Active, not recruiting, 
    Based upon these results, a follow up study [NCT04506567] testing multiple and fractionated dosing of 225Ac-J591 is underway. Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2021 --> Jan 2021
  • ||||||||||  SPX-106T / Spherix
    Journal:  Preparation of CLEAs and magnetic CLEAs of a recombinant l-arabinose isomerase for d-tagatose synthesis. (Pubmed Central) -  Jan 16, 2021   
    The best results were achieved when the m-CLEA was produced with 20 mg of MNP, 7.69 U. g of enzymatic activity, 7.61 % of recovered activity, 99 % of yield of immobilization. On the other hand, the enzyme immobilized onto MNP-APTES, presented only 2.12 U. g of enzymatic activity, 32.3 % of recovered activity, and 15 % of yield of immobilization.
  • ||||||||||  Ac-225 rosopatamab tetraxetan (CONV01-?) / Dominari Holdings
    Enrollment open:  Re-treatment 225Ac-J591 for mCRPC (clinicaltrials.gov) -  Nov 22, 2020   
    P1,  N=18, Recruiting, 
    With these interesting catalytic properties, this enzyme could be a promising candidate for industrial biocatalytic applications. Not yet recruiting --> Recruiting
  • ||||||||||  SPX-106T / Spherix
    Journal:  Engineered Bacillus subtilis harbouring gene of d-tagatose 3-epimerase for the bioconversion of d-fructose into d-psicose through fermentation. (Pubmed Central) -  Nov 12, 2020   
    After optimizing the fermentation conditions of the recombinant strain, the yield of d-psicose reached up to 4.56 g/L, representing an over 8-fold increase in the yield compared to unoptimized conditions, with a d-fructose conversion rate of 56.26 % when the strain was cultured at 35 ℃ for 24 h with 5 g/L d-fructose and 5 mM of Mn. In addition, 30 g of wasted apple hydrolysate were fermented by engineered B. subtilis and gained 7.76 g/L of d-psicose at a conversion rate of 25.86 % (w/w).
  • ||||||||||  Ac-225 rosopatamab tetraxetan (CONV01-?) / Dominari Holdings
    New P1 trial:  Re-treatment 225Ac-J591 for mCRPC (clinicaltrials.gov) -  Oct 5, 2020   
    P1,  N=18, Not yet recruiting, 
  • ||||||||||  Ac-225 rosopatamab tetraxetan (CONV01-?) / Dominari Holdings
    Enrollment open, Metastases:  Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC (clinicaltrials.gov) -  Sep 27, 2020   
    P1/2,  N=105, Recruiting, 
    The findings establish the utility of GC-MS together with mass spectral libraries as a powerful technology platform to determine the authenticity, and create market protection, for "Mozzarella di Bufala Campana." Not yet recruiting --> Recruiting
  • ||||||||||  SPX-106T / Spherix
    Review, Journal:  Non-nutritive sweeteners for diabetes mellitus. (Pubmed Central) -  Sep 13, 2020   
    There is inconclusive evidence of very low certainty regarding the effects of NNS consumption compared with either sugar, placebo, or nutritive low-calorie sweetener consumption on clinically relevant benefit or harm for HbA1c, body weight, and adverse events in people with type 1 or type 2 diabetes. Data on health-related quality of life, diabetes complications, all-cause mortality, and socioeconomic effects are lacking.
  • ||||||||||  SPX-106T / Spherix
    Journal:  N-(carboxymethyl)lysine formation from the Maillard reaction of casein and different reducing sugars. (Pubmed Central) -  Apr 17, 2020   
    The results reveal that tagatose leads to a lower CML concentration at 75 °C than glucose or xylose, whereas no significant differences are observed at 120 °C. We conclude that it would be more appropriate to use tagatose rather than glucose or xylose as a sweetener, considering the AGEs contents in heat-treated dairy products.
  • ||||||||||  SPX-106T / Spherix
    Journal:  The Constipation-Relieving Property of d-Tagatose by Modulating the Composition of Gut Microbiota. (Pubmed Central) -  Apr 10, 2020   
    Moreover, the 16S rRNA sequencing analysis revealed that the changes in the gut microbiota caused by constipation were restored by d-tagatose treatment. In conclusion, this study indicated that the administration of d-tagatose as a dietary supplement can effectively prevent and relieve constipation in Kunming mice, and it is a promising prebiotic candidate with constipation-relieving properties.
  • ||||||||||  SPX-106T / Spherix
    Journal:  Ecological impact of a rare sugar on grapevine phyllosphere microbial communities. (Pubmed Central) -  Mar 31, 2020   
    Among rare sugars, tagatose (TAG) is a low-calories sweetener that stimulates and inhibits beneficial and pathogenic bacteria in the human gut microbiota, respectively...TAG is a promising biopesticide that could shift the balance of pathogenic and beneficial plant-associated microorganisms, suggesting selective nutritional/anti-nutritional properties for some specific taxa. More specifically, TAG displayed possible plant prebiotic effects on the phyllosphere microbiota and this mechanism of action could represent a novel strategy that can be further developed for sustainable plant protection.
  • ||||||||||  SPX-106T / Spherix
    Journal:  The Rare Sugar Tagatose Differentially Inhibits the Growth of Phytophthora infestans and Phytophthora cinnamomi by Interfering With Mitochondrial Processes. (Pubmed Central) -  Mar 3, 2020   
    On the other hand, tagatose did not, or only slightly, affect the growth, cellular ultrastructure and mitochondrial processes in Phytophthora cinnamomi, indicating a species-specific response to this rare sugar. The mode of action of tagatose against P. infestans was mainly based on the inhibition of mitochondrial processes and this rare sugar seems to be a promising active substance for the further development of eco-friendly fungicides, thanks to its anti-nutritional properties on some phytopathogens and low risk for human health.
  • ||||||||||  SPX-106T / Spherix
    Review, Journal:  Review on D-Allulose: In vivo Metabolism, Catalytic Mechanism, Engineering Strain Construction, Bio-Production Technology. (Pubmed Central) -  Mar 3, 2020   
    Rare sugar D-allulose as a substitute sweetener is produced through the isomerization of D-fructose by D-tagatose 3-epimerases (DTEases) or D-allulose 3-epimerases (DAEases)...The existing problems and its proposed solutions for D-allulose production are also discussed. More importantly, a green and recycling process technology for D-allulose production is proposed for low waste formation, low energy consumption, and high sugar yield.
  • ||||||||||  Ac-225 rosopatamab tetraxetan (CONV01-?) / Dominari Holdings
    Trial completion date, Trial primary completion date, Metastases:  7R01CA207645-03: Phase I Trial of 225Ac-J591 in Patients With mCRPC (clinicaltrials.gov) -  Mar 3, 2020   
    P1,  N=42, Recruiting, 
    More importantly, a green and recycling process technology for D-allulose production is proposed for low waste formation, low energy consumption, and high sugar yield. Trial completion date: Jul 2021 --> Jul 2024 | Trial primary completion date: Dec 2019 --> Dec 2021
  • ||||||||||  lactulose / Generic mfg., SPX-106T / Spherix
    Journal:  One-pot synthesis of sweetening syrup from lactose. (Pubmed Central) -  Feb 21, 2020   
    The one-pot synthesis, enzymatic hydrolysis and catalytic isomerization over 20%-MgO/SiO, converted 99.3% of lactose into a sweetening syrup made of glucose (30.48%), galactose (33.51%), fructose (16.92%), D-tagatose (10.54%), and lactulose (3.62%). The outcomes of this research present an opportunity for expanding the utilization of lactose.